A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify 10 mg Tablet in Healthy Volunteers

Trial Profile

A Single-dose, Randomized, Three-period, Crossover Comparative Bioavailability Study of a Novel Formulation of Aripiprazole 10 mg Oral Soluble Film vs the Marketed Formulation Abilify 10 mg Tablet in Healthy Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 30 Mar 2016

At a glance

  • Drugs Aripiprazole (Primary)
  • Indications Schizophrenia
  • Focus Pharmacokinetics
  • Sponsors CMG Pharmaceutical
  • Most Recent Events

    • 23 Mar 2016 Protocol amended as treatment arms changed from 1 to 3, study design changed from single group to crossover assignment as reported by ClinicalTrials.gov.
    • 23 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 26 Oct 2015 Planned End Date changed from 1 Dec 2015 to 1 Apr 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top